10 days of MPFC TMS improves treatment outcome in AUD

The primary conclusions of this randomized, double-blind, sham-controlled longitudinal study are that 10 sessions of FP1 TBS 1) are well tolerated and a feasible addition to an intensive outpatient treatment program, 2) increased treatment engagement and sobriety 3 months after treatment initiation, and 3) produced a significant and durable decrease in alcohol cue–associated functional connectivity from the FP1 to the same network of regions that were modified in the single-session study. These data suggest that the FP1 continues to be a promising clinical treatment target for individuals with AUD and underscores the need for large multisite trials to evaluate this as a treatment adjuvant.